Predicting time to full-time care in AD: a new model

References

• Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. Int J Geriatr Psychiatry 1998; 13: 445–453
   PubMed Web of Science ®Google Scholar
• Jönsson L, Lindgren P, Wimo A, et al. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clin Ther 1999; 21: 1230–1240
   PubMed Web of Science ®Google Scholar
• Teipel SJ, Ewers M, Reisig V, et al. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 2007; 257: 330–336
   PubMed Web of Science ®Google Scholar
• Fenn P, Gray A. Estimating long-term cost savings from treatment of Alzheimer's disease. A modelling approach. Pharmacoeconomics 1999; 16: 165–174
   PubMed Web of Science ®Google Scholar
• Livingston G, Katona C, Roch B, et al. A dependency model for patients with Alzheimer's disease: its validation and relationship to the costs of care – the LASER–AD Study. Curr Med Res Opin 2004; 20: 1007–1016
   PubMed Web of Science ®Google Scholar
• Small GW, McDonnell DD, Brooks RL, et al. The impact of symptom severity on the cost of Alzheimer's disease. J Am Geriatr Soc. 2002; 50: 321–327
   PubMed Web of Science ®Google Scholar
• Jönsson L, Jönhagen ME, Kilander L, et al. Determinants of costs of care for patients with Alzheimer's disease. Int J Geriatr Psychiatry 2006; 21: 449–459
   PubMed Web of Science ®Google Scholar
• Rozzini L, Cornali C, Chilovi BV, et al. Predictors of institutionalization in demented patients discharged from a rehabilitation unit. J Am Med Dir Assoc 2006; 7: 345–349
   PubMed Web of Science ®Google Scholar
• Zhu CW, Scarmeas N, Torgan R, et al. Clinical features associated with costs in early AD: baseline data from the Predictors Study. Neurology 2006; 66: 1021–1028
   PubMed Web of Science ®Google Scholar
• Ikeda S, Yamada Y, Ikegami N. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan. Dement Geriatr Cogn Disord 2002; 13: 33–39
   PubMed Web of Science ®Google Scholar
• López-Bastida J, Hart W, García-Pérez L, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. J Alzheimers Dis 2009; 16: 399–407
   PubMed Web of Science ®Google Scholar
• Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566–572
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999; 52: 1138–1145
   PubMed Web of Science ®Google Scholar
• François C, Sintonen H, Sulkava R, et al. Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease: a Markov model in Finland. Clin Drug Investig 2004; 24: 373–384
   PubMed Web of Science ®Google Scholar
• Jones RW, McCrone P, Guilhaume C, et al. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging 2004; 21: 607–620
   PubMed Web of Science ®Google Scholar
• Jönsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. Am J Geriatr Pharmacother 2005; 3: 77–86
   PubMedGoogle Scholar
• Gagnon M, Rive B, Hux M, et al. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry 2007; 52: 519–526
   PubMed Web of Science ®Google Scholar
• Stern Y, Tang MX, Albert MS, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997; 277: 806–812
   PubMed Web of Science ®Google Scholar
• Caro JJ, Getsios D, Migliaccio-Walle K, et al. Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care. Neurology 2001; 57: 964–971
   PubMed Web of Science ®Google Scholar
• Getsios D, Caro JJ, Caro G, et al. AHEAD Study Group. Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada. Neurology 2001; 57: 972–978
   PubMed Web of Science ®Google Scholar
• Migliaccio-Walle K, Getsios D, Caro JJ, et al. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin Ther 2003; 25: 1806–1825
   PubMed Web of Science ®Google Scholar
• Ward A, Caro JJ, Getsios D, et al. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. Int J Geriatr Psychiatry 2003; 18: 740–747
   PubMed Web of Science ®Google Scholar
• Caro JJ, Salas M, Ward A, et al. Assessment of health economics in Alzheimer's disease. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands. Dement Geriatr Cogn Disord 2002; 14: 84–89
   PubMed Web of Science ®Google Scholar
• Garfield FB, Getsios D, Caro JJ, et al. Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden. Pharmacoeconomics 2002; 20: 629–637
   PubMed Web of Science ®Google Scholar
• Caro J, Salas M, Ward A, et al. Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries. Drugs Aging 2004; 2: 677–686
   Google Scholar
• Green C. Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis. Pharmacoeconomics 2007; 25: 735–750
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198
   PubMed Web of Science ®Google Scholar
• Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356–1364
   PubMed Web of Science ®Google Scholar
• Saxton J, Swihart AA. Neuropsychological assessment of the severely impaired elderly patient. Clin Geriatr Med 1989; 5: 531–543
   PubMedGoogle Scholar
• Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(Suppl 2)S33–39
   PubMed Web of Science ®Google Scholar
• Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308–2314
   PubMed Web of Science ®Google Scholar
• Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study – clinical global impression of change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(Suppl 2)S22–32
   Google Scholar
• Knopman DS, Knapp MJ, Gracon SI, et al. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994; 44: 2315–2321
   PubMed Web of Science ®Google Scholar
• Diesfeldt HF. Observations on behavior, psychological study and 1-year survival in psychogeriatric patients. Gerontologie 1980; 11: 205–212
   PubMedGoogle Scholar
• Beecham J, Knapp MRJ. Costing psychiatric intervention. Measuring Mental Health Needs, GJ Thornicroft, CR Brewin, JK Wing. Gaskell/Royal College of Psychiatrists, London 1992
   Google Scholar
• Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data, 2nd. Wiley, New York 2002
   Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361–370
   PubMed Web of Science ®Google Scholar
• Wimo A, Wetterholm AL, Mastey V, . Evaluation of the resource utilization and caregiver time in anti-dementia drug trials: a quantitative battery. Health Economics of Dementia, A Wimo, B Jönsson, G Karlsson, B Winblad, et al. John Wiley & Sons, London 1988; 465–99
   Google Scholar
• Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias. Committee for Medicinal Products for Human Use (CHMP), 2008. London: doc. ref. cpmp/ewp/553/595 rev. 551.
   Google Scholar
• Vellas B, Coley N, Andrieu S. Disease modifying trials in Alzheimer's disease: perspectives for the future. J Alzheimer's Dis 2008; 15: 289–301
   PubMed Web of Science ®Google Scholar
• Scarmeas N, Brandt J, Albert M, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol 2005; 62: 1601–1608
   PubMedGoogle Scholar
• Scarmeas N, Brandt J, Blacker D, et al. Disruptive behaviour as a predictor in Alzheimer's disease. Arch Neurol 2007; 64: 1755–1761
   PubMed Web of Science ®Google Scholar
• Habermann S, Cooper C, Katona C, et al. Predictors of entering 24-h care for people with Alzheimer's disease: results from the LASER–AD study. Int J Geriatr Psychiatry 2009; 24: 1291–1298
   PubMed Web of Science ®Google Scholar